Canakinumab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 150 mg/mL
Reference Brands: Ilaris (USA/EU)
Category: Immune Disorder
Canakinumab is a monoclonal antibody that targets interleukin-1β to reduce inflammation in various autoinflammatory disorders. It is used for conditions such as CAPS, Still’s disease, gout flares, and certain periodic fever syndromes. The drug is administered subcutaneously in controlled doses according to the specific indication. Canakinumab is available in Injection and strengths such as 150 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Canakinumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Canakinumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Canakinumab is used to treat several inflammatory conditions such as Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterranean Fever (FMF), Still’s disease, and certain forms of gouty arthritis. It works by blocking interleukin-1β, a key mediator of inflammation.
Canakinumab is made from a fully human monoclonal antibody specifically designed to neutralize interleukin-1β and reduce inflammation in the body.
The commonly known trade name is Ilaris.
Ilaris is manufactured and marketed by Novartis Pharmaceuticals.
The generic name is canakinumab.
The well-known brand name is Ilaris.
Canakinumab is manufactured in various Novartis facilities located in Switzerland, the USA, and other regulated global manufacturing regions.
Related Products
Sarilumab
Strength:
150 mg/1.14 mL, 200 mg/1.14 mL
Form: injection (prefilled syringe)
Reference Brands: Kevzara (USA/EU)
View Details
Quick Response Guaranteed | Verified Suppliers
